SN BioScience

About SN BioScience

Established in May 2017 by CEO Young-hwan Park, SN BioScience is a clinical-stage biotechnology firm located in Seongnam, South Korea, specializing in drug delivery systems for cancer therapeutics. Park, who holds a degree in pharmacy, leveraged approximately 20 years of experience in the pharmaceutical industry, including non-clinical and clinical research, drug delivery technology, and the commercialization of anticancer drugs, to found the company. His expertise in pharmacokinetics and nano-drug delivery technologies like liposomes and nanoparticles serves as the foundation for the company's research and development focus.

SN BioScience's business model centers on developing and commercializing advanced drug formulations for challenging medical needs. The company's core competency lies in its proprietary nano-drug delivery platforms, which include dual nano-micelle technology, albumin nanoparticle technology, and sustained-release liposome technology. This is supported by its PCI-Metric technology, a decision-making process used to optimize drug delivery solutions. The company has successfully overcome significant manufacturing hurdles, such as the scale-up production for nano-cancer drugs, and produces its clinical trial materials in an EU GMP-certified facility. Revenue is generated through out-licensing agreements for its drug candidates.

The company's lead product candidate is SNB-101, the first nanoparticle formulation of SN-38, the active metabolite of the anticancer drug irinotecan. This formulation, utilizing a double core-shell micelle technology, aims to improve the solubility and safety of SN-38, potentially reducing adverse events and allowing for its use in new cancer indications like lung, pancreatic, and stomach cancers. SNB-101 has received Orphan Drug and Fast Track designations from the U.S. FDA for small cell lung cancer (SCLC) and is advancing to Phase 2 clinical trials in the U.S., Europe, and South Korea, with a potential U.S. market entry targeted for 2028. Other pipeline products include SNA-001 for pancreatic cancer, SNA-002, a liposomal formulation for post-surgery pain, and SNA-003 for metabolic diseases.